Back to Search Start Over

Surgical treatment for clinical early-stage expansile and infiltrative mucinous ovarian cancer

Source :
Current Opinion in Oncology. 34(5):497-503
Publication Year :
2022
Publisher :
LIPPINCOTT WILLIAMS & WILKINS, 2022.

Abstract

PURPOSE OF REVIEW: Mucinous ovarian cancers (MOCs) are categorized into infiltrative and expansile subtypes. These subtypes have different characteristics and prognoses. Patients with clinical early-stage disease of both subtypes currently undergo surgical staging (peritoneal washing, biopsies, omentectomy). Peritoneal and lymph node metastases of expansile MOC are rare, but whereas lymph node sampling (LNS) is omitted in these patients, peritoneal staging is not. Therefore, we collected all available MOC data to determine whether staging surgeries could safely be omitted in clinical early-stage expansile and infiltrative MOC.RECENT FINDINGS: Current literature confirms that peritoneal metastases are rare in expansile MOC: more than 90% had early-stage disease. Only 3.4% of the patients with clinical early-stage expansile MOC had positive peritoneal washings at surgical staging. Patients with infiltrative MOC were diagnosed more frequently with advanced-stage disease (21-54%). Moreover, upstaging clinical early-stage infiltrative MOC based on positive cytology, peritoneum and omentum metastases occurred in 10.3% of the patients. Therefore, we recommend that patients with early-stage infiltrative MOC undergo peritoneal staging and LNS. However, in addition to omitting LNS, we can also safely recommend omitting peritoneal staging in patients with early-stage expansile MOC.SUMMARY: Peritoneal metastases are rare in clinical early-stage expansile MOC and peritoneal staging can therefore safely be omitted.

Details

Language :
English
ISSN :
10408746
Volume :
34
Issue :
5
Database :
OpenAIRE
Journal :
Current Opinion in Oncology
Accession number :
edsair.od........83..543500f3fe7f767237217681313c4166